E-ISSN 2218-6050 | ISSN 2226-4485
 

Research Article


Anti-tumor effects of lapatinib on HER2-positive canine prostatic carcinoma cell lines

Kenjiro Kaji, Tomohiro Yonezawa, Tomohiro Yonezawa, Yasuyuki Momoi, Shingo Maeda.


Abstract
Background:
Canine prostatic carcinoma (cPC) is a urogenital tumor with poor prognosis, for which no effective treatment has been established. Recently, it has been shown that human epidermal growth factor receptor type 2 (HER2) is overexpressed in cPC cells; however, the efficacy of HER2-targeted therapy remains unclear.
Aim:
Investigate the anti-tumor effect of lapatinib on HER2-positive cPC cell lines.
Methods:
Two cell lines (muPC and bePC) were established from two dogs with cPC and the effects of lapatinib treatment on cell proliferation, apoptosis, and HER2 downstream signaling were investigated. Furthermore, muPC was used to generate tumor-bearing mice, and the anti-tumor effects of lapatinib were examined in vivo.
Results:
Lapatinib treatment inhibited the proliferation and phosphorylation of Erk1/2 and Akt, which are downstream signals of HER2. Furthermore, the TUNEL assay showed that lapatinib induced apoptosis in both cell lines. The muPC-engrafted nude mouse model showed that lapatinib significantly inhibited tumor growth and increased the area of necrotic tumor tissue compared to the vehicle-treated groups.
Conclusion:
Lapatinib exerts anti-tumor effects on cPC cells by inhibiting HER-2 signaling.

Key words: Dogs, Human epidermal growth factor receptor type 2, Target therapy, Prostate cancer


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Kenjiro Kaji
Articles by Tomohiro Yonezawa
Articles by Tomohiro Yonezawa
Articles by Yasuyuki Momoi
Articles by Shingo Maeda
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

Kaji K, Yonezawa T, Yonezawa T, Momoi Y, Maeda S. Anti-tumor effects of lapatinib on HER2-positive canine prostatic carcinoma cell lines. Open Vet J. 2024; 14(5): 1259-1268. doi:10.5455/OVJ.2024.v14.i5.21


Web Style

Kaji K, Yonezawa T, Yonezawa T, Momoi Y, Maeda S. Anti-tumor effects of lapatinib on HER2-positive canine prostatic carcinoma cell lines. https://www.openveterinaryjournal.com/?mno=180194 [Access: June 03, 2024]. doi:10.5455/OVJ.2024.v14.i5.21


AMA (American Medical Association) Style

Kaji K, Yonezawa T, Yonezawa T, Momoi Y, Maeda S. Anti-tumor effects of lapatinib on HER2-positive canine prostatic carcinoma cell lines. Open Vet J. 2024; 14(5): 1259-1268. doi:10.5455/OVJ.2024.v14.i5.21



Vancouver/ICMJE Style

Kaji K, Yonezawa T, Yonezawa T, Momoi Y, Maeda S. Anti-tumor effects of lapatinib on HER2-positive canine prostatic carcinoma cell lines. Open Vet J. (2024), [cited June 03, 2024]; 14(5): 1259-1268. doi:10.5455/OVJ.2024.v14.i5.21



Harvard Style

Kaji, K., Yonezawa, . T., Yonezawa, . T., Momoi, . Y. & Maeda, . S. (2024) Anti-tumor effects of lapatinib on HER2-positive canine prostatic carcinoma cell lines. Open Vet J, 14 (5), 1259-1268. doi:10.5455/OVJ.2024.v14.i5.21



Turabian Style

Kaji, Kenjiro, Tomohiro Yonezawa, Tomohiro Yonezawa, Yasuyuki Momoi, and Shingo Maeda. 2024. Anti-tumor effects of lapatinib on HER2-positive canine prostatic carcinoma cell lines. Open Veterinary Journal, 14 (5), 1259-1268. doi:10.5455/OVJ.2024.v14.i5.21



Chicago Style

Kaji, Kenjiro, Tomohiro Yonezawa, Tomohiro Yonezawa, Yasuyuki Momoi, and Shingo Maeda. "Anti-tumor effects of lapatinib on HER2-positive canine prostatic carcinoma cell lines." Open Veterinary Journal 14 (2024), 1259-1268. doi:10.5455/OVJ.2024.v14.i5.21



MLA (The Modern Language Association) Style

Kaji, Kenjiro, Tomohiro Yonezawa, Tomohiro Yonezawa, Yasuyuki Momoi, and Shingo Maeda. "Anti-tumor effects of lapatinib on HER2-positive canine prostatic carcinoma cell lines." Open Veterinary Journal 14.5 (2024), 1259-1268. Print. doi:10.5455/OVJ.2024.v14.i5.21



APA (American Psychological Association) Style

Kaji, K., Yonezawa, . T., Yonezawa, . T., Momoi, . Y. & Maeda, . S. (2024) Anti-tumor effects of lapatinib on HER2-positive canine prostatic carcinoma cell lines. Open Veterinary Journal, 14 (5), 1259-1268. doi:10.5455/OVJ.2024.v14.i5.21